This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kohlhoff, S. A.
Right arrow Articles by Hammerschlag, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kohlhoff, S. A.
Right arrow Articles by Hammerschlag, M. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2004, p. 1885-1886, Vol. 48, No. 5
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.5.1885-1886.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of a Novel Diaminopyrimidine Compound, Iclaprim, against Chlamydia trachomatis and C. pneumoniae

S. A. Kohlhoff,1* P. M. Roblin,1 T. Reznik,1 S. Hawser,2 K. Islam,2 and M. R. Hammerschlag1

Department of Pediatrics, Downstate Medical Center, State University of New York, Brooklyn, New York,1 Arpida, Ltd., Münchenstein, Switzerland2

Received 19 November 2003/ Returned for modification 24 December 2003/ Accepted 29 January 2004

The in vitro activities of iclaprim, a novel dihydrofolate reductase inhibitor, azithromycin, and levofloxacin were tested against 10 strains of Chlamydia trachomatis and 10 isolates of Chlamydia pneumoniae. For C. trachomatis and C. pneumoniae, the iclaprim MIC and minimal bactericidal concentration at which 90% of isolates were inhibited (MIC90 and MBC90) were 0.5 µg/ml, compared to an azithromycin MIC90 and MBC90 of 0.125 µg/ml and levofloxacin MIC90s and MBC90s of 1 µg/ml for C. trachomatis and 0.5 µg/ml for C. pneumoniae.

* Corresponding author. Mailing address: Department of Pediatrics, Box 49, SUNY Downstate Medical Center, 450 Clarkson Ave., Brooklyn, NY 11203-2098. Phone: (718) 270-7588. Fax: (718) 270-3210. E-mail: stephan.kohlhoff{at}downstate.edu.

Antimicrobial Agents and Chemotherapy, May 2004, p. 1885-1886, Vol. 48, No. 5
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.5.1885-1886.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Zhanel, G. G., Karlowsky, J. A. (2009). In Vitro Activity of Iclaprim against Respiratory and Bacteremic Isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 53: 1690-1692 [Abstract] [Full Text]  
  • Laue, H., Valensise, T., Seguin, A., Hawser, S., Lociuro, S., Islam, K. (2007). Effect of human plasma on the antimicrobial activity of iclaprim in vitro. J Antimicrob Chemother 60: 1388-1390 [Abstract] [Full Text]  
  • Laue, H., Weiss, L., Bernardi, A., Hawser, S., Lociuro, S., Islam, K. (2007). In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action. J Antimicrob Chemother 60: 1391-1394 [Abstract] [Full Text]  
  • Morrissey, I., Hawser, S. (2007). Activity of iclaprim against Legionella pneumophila. J Antimicrob Chemother 60: 905-906 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»